More recently, an analysis of the FDA adverse event report system database found that patients with type 2 diabetes on SGLT-2 inhibitors were at a significantly greater risk of AKI compared to those who were not treated with SGLT-2 inhibitors [10]. This evidence concerns the gene SLC5A2 and type 2 diabetes mellitus.